Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037490 | 0.89 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL4884668 | 0.83 | ADRB3 (0.79) | ADRB3 | |
| SCHEMBL7037443 | 0.83 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7039402 | 0.83 | ADRB3 (0.94) | ADRB3 | |
| SCHEMBL5209785 | 0.82 | ADRB3 (0.64) | ADRB3 | |
| SCHEMBL7039307 | 0.82 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7113996 | 0.82 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7113998 | 0.82 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7042311 | 0.82 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7039312 | 0.82 | ADRB3 (1.00) | ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105309-A1 | Medicinal Compounds | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-1675823-B1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | ADRB3 6/4885 |
| US-20090105309-A1 | Medicinal Compounds | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.